Classification and characterization of patient suffering from moderate to severe plaque psoriasis responding to subcutaneous administered efalizumab - ROCAC

Investigator Trondheim Hudlegesenter AS0 个研究点目标入组 150 人开始时间: 2006年6月19日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•The study population consists of patients of both genders, over the age of 18 years who have been suffering from stable moderate to severe plaque psoriasis for more than six months and who are eligible for efalizumab treatment according to current national guidelines, i.e. the patients have not responded to, have contraindications to or are intolerant to other systemic treatment, including cyklosporin, methotrexat and PUVA.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•* Pregnant or breast-feeding patients.
•* Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
•* Patients suffering from HIV, hepatitis B and C, active tuberculosis (TB) or currently undergoing treatment for TB, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.
•* Patients with history of cancer in the preceding 5 years, including lymphproliferative disorders. Patients with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
•* Patients to whom subcutaneous administered efalizumab treatments are contraindicated.

发起方

Investigator Trondheim Hudlegesenter AS